Suryatheja Ananthula

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

ChemistryMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides”.

Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides

Frontiers in Immunology(2021)10.3389/fimmu.2020.629399

N/A

0DataRank · unranked

33 citations

Suryatheja Ananthula, Ramesh Venna, Swamy K. Polumuri, Elliot Mattson, Lacey M. Walker +14 more

Development of mouse models with restricted HLA-B∗57:01 presentation for the study of flucloxacillin-driven T-cell activation and tolerance in liver injury

Journal of Allergy and Clinical Immunology(2023)10.1016/j.jaci.2023.03.029

N/A

0DataRank · unranked

14 citations

Kirthiram Krishnaveni Sivakumar, Marco Cardone, Shan Su, Gregory Roderiquez, Hanan Abuzeineh +4 more

FDA Approval Summary: Vorasidenib for IDH -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1333

N/A

0DataRank · unranked

12 citations

Amy Barone, Stephanie Aungst, Claudia P. Miller, Suryatheja Ananthula, Youwei Bi +20 more